Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. is a biotechnology and pharmaceutical startup that focuses on developing therapeutics for patients suffering from rare and severe metabolic and kidney disorders. Founded in 2011 and headquartered in the United States, the company's mission is to address metabolic disorders leading to the excess accumulation of certain metabolites, such as oxalate and urate, which can cause kidney stones, kidney damage, and potential progression to chronic kidney disease (CKD) and end-stage renal disease. Allena Pharmaceuticals utilizes a proprietary technological approach to design, formulate, and deliver non-absorbed and stable enzymes orally in adequate doses for activity in the gastrointestinal (GI) tract. This approach aims to degrade metabolites in the GI tract, reducing plasma and urine levels of oxalate and urate and subsequently lessening their disease burden on the kidneys over time. The startup has recently secured a $2.80M post-IPO equity investment on May 4, 2022. The investors for this round are not specified. Overall, Allena Pharmaceuticals strives to make significant advancements in treating rare metabolic disorders and kidney-related conditions through its innovative therapeutic approach.